By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Proteon Therapeutics, Inc. 

4420 Madison Avenue
Suite 180
Kansas City  Missouri  64111  U.S.A.
Phone: 816-531-0028 Fax: 816-531-3079



Company News
Proteon Therapeutics, Inc. Initiates Phase 3 Clinical Study Of PRT-201 In Patients With Chronic Kidney Disease Undergoing Surgical Placement Of An Arteriovenous Fistula For Hemodialysis 7/21/2014 11:14:02 AM
Proteon Therapeutics, Inc. Announces $45 Million Of Series D Financing 5/16/2014 7:19:26 AM
Proteon Therapeutics, Inc. Announces Publication Of Results From Phase 2 Study Of PRT-201 5/14/2014 8:35:52 AM
Proteon Therapeutics, Inc., Looking Past Ill-Fated Novartis AG (NVS) Deal, Goes It Alone 3/18/2014 7:33:36 AM
Proteon Therapeutics, Inc. Announces Orphan Drug Designation In The European Union For PRT-201 1/8/2014 10:20:52 AM
Proteon Therapeutics, Inc. Announces Positive Phase 2 Trial Results of PRT-201 in Chronic Kidney Disease Patients Undergoing Surgical Placement of an Arteriovenous Fistula for Hemodialysis 1/4/2013 9:52:43 AM
Awaiting Novartis AG Acquisition, Biotech Firm Proteon Therapeutics, Inc. Raises $15.2 Million 8/12/2011 8:04:43 AM
Proteon Therapeutics, Inc. Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients 4/14/2011 12:38:48 PM
Proteon Therapeutics, Inc. Named 2010 Technology Pioneer by the World Economic Forum 12/3/2009 9:08:16 AM
Proteon Therapeutics, Inc. Completes Second Closing of Equity Financing; Raises Total Series B to $50 Million 5/28/2009 7:27:50 AM